Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05362929 · ClinicalTrials.gov registry record · NA

Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color

A NA study of Acne Scars - Mixed Atrophic and Hypertrophic and Hyperpigmentation, sponsored by Albert Einstein College of Medicine.

Recruiting
Registry status
NA
Development phase
46
Enrollment target
1
Study location

NCT05362929 is a NA study of Acne Scars - Mixed Atrophic and Hypertrophic and Hyperpigmentation that is actively recruiting participants, run by Albert Einstein College of Medicine. The registered enrollment target is 46 participants, below the 105-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05362929, a NA study of Acne Scars - Mixed Atrophic and Hypertrophic and Hyperpigmentation, is actively recruiting participants, sponsored by Albert Einstein College of Medicine.

RECRUITING
Registry status
NA
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

The investigators aim to investigate the efficacy and tolerability of a hybrid non-ablative/ablative laser for acne scarring in skin of color.

Interventions

  • DEVICE Sciton Halo

Study Locations (1)

New York

  • 555 Taxter Road - Elmsford

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2023-10-11
Est. Completion 2026-09
Phase NA

Sponsor

Albert Einstein College of Medicine

175 total trials

What the Registry Record Tells You About NCT05362929

The ClinicalTrials.gov registry entry for NCT05362929 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (56% lower). The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acne Scars - Mixed Atrophic and Hypertrophic appearing as the primary indexed condition, and to 1 intervention - of which Sciton Halo is the first listed.

NCT05362929 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05362929 about?

NCT05362929 is a clinical study titled "Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color". The investigators aim to investigate the efficacy and tolerability of a hybrid non-ablative/ablative laser for acne scarring in skin of color.

What is the current status of trial NCT05362929?

This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2023-10-11. Estimated completion is 2026-09.

What conditions does trial NCT05362929 study?

This clinical trial studies the following conditions: Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation, Laser-Induced Hyperpigmentation.

What interventions are being tested in trial NCT05362929?

The interventions under investigation include: Sciton Halo (DEVICE).

Who is sponsoring clinical trial NCT05362929?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05362929 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne Scars - Mixed Atrophic and Hypertrophic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.